DGAP-News: MorphoSys AG / Key word(s): Conference Planegg/Munich, Germany, December 5, 2017 MorphoSys to Host Investor & Analyst Call on December 12, 2017 about Data on MOR208 presented at the 2017 ASH Annual Meeting
In the call the MorphoSys Management will present and discuss updated clinical data from the ongoing phase 2 L-MIND trial with the Company's investigational program MOR208 in combination with lenalidomide in patients with relapsed or refractory diffuse large B cell lymphoma (R/R DLBCL), which had been presented in a poster at the 2017 ASH Annual Meeting in Atlanta on December 11th. Dial-in numbers (listen only): Germany: +49 89 2444 32975 Participants are kindly requested to dial in up to 10 minutes before the call to ensure a prompt start and a secure line. The presentation slides and webcast link will be available at the Company's website at www.morphosys.com/conference-calls A slide-synchronized audio replay of the conference will also be available at the corporate website following the live event.
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group. This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned. For more information, please contact: Anke Linnartz Jochen Orlowski Alexandra Goller Tel: +49 (0) 89 / 899 27-404 05.12.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | MorphoSys AG |
Semmelweisstr. 7 | |
82152 Planegg | |
Germany | |
Phone: | +49 (0)89 899 27-0 |
Fax: | +49 (0)89 899 27-222 |
E-mail: | investors@morphosys.com |
Internet: | www.morphosys.com |
ISIN: | DE0006632003 |
WKN: | 663200 |
Indices: | TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |